Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- fever/chills
- night sweats, malaise, fatigue, anorexia, weight loss, myalgias
- weakness
- arthralgias
- headache
- shortness of breath
- meningeal signs
- cardiac murmur
- Janeway lesions
- Osler nodes
- Roth spots
Outros fatores diagnósticos
- splinter hemorrhages
- cutaneous infarcts
- chest pain
- back pain
- palatal petechiae
Fatores de risco
- prior history of infectious endocarditis
- presence of artificial prosthetic heart valves
- certain types of congenital heart disease
- postheart transplant (patients who develop a cardiac valvulopathy)
- immunocompromised state
- presence of cardiac implanted electronic device or intravascular catheters (e.g., for hemodialysis)
- acquired degenerative valve disease
- mitral valve prolapse or bicuspid valve prolapse
- hypertrophic cardiomyopathy
- intravenous drug use
- chronic Q fever
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- blood cultures
- echocardiogram
- CBC
- CRP
- serum chemistry panel with glucose
- LFTs
- urinalysis
- ECG
Investigações a serem consideradas
- rheumatoid factor
- erythrocyte sedimentation rate
- complement levels
- cardiac CT
- MRI
- nuclear imaging and PET
- specific tests for blood culture-negative endocarditis
Novos exames
- mean platelet volume (MPV)
- anti‐beta-2‐glycoprotein I antibodies
- D-dimer and troponin I
Algoritmo de tratamento
suspected infective endocarditis
native valve: confirmed endocarditis
prosthetic valve: confirmed endocarditis
at high risk of infective endocarditis
Colaboradores
Consultores especialistas
Carl Zehner, MD
Assistant Professor of Medicine
University of Texas MD Anderson Cancer Center
Department of Cardiology
Houston, TX
Declarações
CZ declares that he has no competing interests.
Agradecimentos
Dr Carl Zehner would like to gratefully acknowledge Dr Ammara Mushtuq, Dr Tracey Keteepe-Arachi, Dr Aneil Malhotra, Dr Michael Papadakis, Professor Sanjay Sharma, Dr Jason C. Schultz, Dr Nisha K. Lassi, and Dr Nandan S. Anavekar, previous contributors to this topic.
Declarações
TKA, MP, SS, JCS, NKL, and NSA declare that they have no competing interests. AMu declares that she is Principal Investigator on a grant from Merck on ceftolozane-tazobactam, writer for the Lancet family of journals, question writer for Blueprint Test preparations, and a peer-reviewer for Clinical Overviews, Elsevier (topics influenza and HIV). AMa is an author of a number of references cited in this topic.
Revisores
Vandana Desai, MD
Professor of Pediatrics
SMIMER Hospital
Gujarat
India
Declarações
VD declares that she has no competing interests.
Lucieni Oliveira Conterno, MD, PhD
Director
Clinical Epidemiology Unit
Marilia Medical School
Sao Paulo
Brazil
Divulgaciones
LOC declares that she has no competing interests.
Andrew Wang, MD
Associate Professor of Medicine
Director, Cardiovascular Disease Fellowship Program
Duke University Medical Center
Durham, NC
Divulgaciones
AW declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86.Texto completo Resumen
Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042.Texto completo Resumen
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021 Feb 2;143(5):e72-227.Texto completo Resumen
Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

Diferenciales
- Rheumatic fever
- Atrial myxoma
- Libman-Sacks endocarditis
Más DiferencialesGuías de práctica clínica
- Blood culture-negative endocarditis
- 2023 ESC guidelines for the management of endocarditis
Más Guías de práctica clínicaVideos
Venepuncture and phlebotomy: animated demonstration
How to perform an ECG: animated demonstration
Más vídeosFolletos para el paciente
Endocarditis
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad
